These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 18069036)

  • 1. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II).
    Hadji P; Minne H; Pfeifer M; Bourgeois P; Fardellone P; Licata A; Devas V; Masanauskaite D; Barrett-Connor E
    Joint Bone Spine; 2008 May; 75(3):303-10. PubMed ID: 18069036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).
    Emkey R; Koltun W; Beusterien K; Seidman L; Kivitz A; Devas V; Masanauskaite D
    Curr Med Res Opin; 2005 Dec; 21(12):1895-903. PubMed ID: 16368038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Korean J Intern Med; 2011 Sep; 26(3):340-7. PubMed ID: 22016595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
    Chung YS; Lim SK; Chung HY; Lee IK; Park IH; Kim GS; Min YK; Kang MI; Chung DJ; Kim YK; Choi WH; Shong MH; Park JH; Byun DW; Yoon HK; Shin CS; Lee YS; Kwon NH
    Calcif Tissue Int; 2009 Nov; 85(5):389-97. PubMed ID: 19816648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
    Miller PD; Epstein S; Sedarati F; Reginster JY
    Curr Med Res Opin; 2008 Jan; 24(1):207-13. PubMed ID: 18042311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study.
    Cooper A; Drake J; Brankin E;
    Int J Clin Pract; 2006 Aug; 60(8):896-905. PubMed ID: 16800837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO).
    Iwamoto J; Okano H; Furuya T; Urano T; Hasegawa M; Hirabayashi H; Kumakubo T; Makita K
    J Bone Miner Metab; 2016 Mar; 34(2):201-8. PubMed ID: 25794468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
    Binkley N; Martens MG; Silverman SL; Derman RJ; Greenwald M; Kohles JD; Bachmann GA
    South Med J; 2009 May; 102(5):486-92. PubMed ID: 19373149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia.
    Vlak T; Kaštelan D; Lozo P; Aljinović J; Gradišer M; Mijić S; Nikolić T; Miškić B; Car D; Tajšić G; Dušek T; Jajić Z; Grubišić F; Poljičanin T; Bakula M; Džubur F; Strižak-Ujević M; Kadojić M; Radman M; Vugrinec M; Kuster Z; Pekez M; Radović E; Labar L; Crnčević-Orlić Z; Koršić M
    Clin Rheumatol; 2011 Dec; 30(12):1549-54. PubMed ID: 21956235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
    Hadji P; Felsenberg D; Amling M; Hofbauer LC; Kandenwein JA; Kurth A
    Osteoporos Int; 2014 Jan; 25(1):339-47. PubMed ID: 24091594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study.
    Kastelan D; Lozo P; Stamenkovic D; Miskic B; Vlak T; Kolak Z; Milas Ahic J; Altabas V; Crncevic Orlic Z; Korsic M
    Clin Rheumatol; 2009 Mar; 28(3):321-6. PubMed ID: 19031095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis.
    Guañabens N; Monegal A; Cerdá D; Muxí Á; Gifre L; Peris P; Parés A
    Hepatology; 2013 Dec; 58(6):2070-8. PubMed ID: 23686738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.
    Bonnick SL; Silverman S; Tanner SB; Martens M; Bachmann G; Kohles JD; Civitelli R
    J Womens Health (Larchmt); 2009 Jul; 18(7):935-43. PubMed ID: 19563245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-monthly dosing: an effective step forward.
    Reid DM
    Bone; 2006 Apr; 38(4 Suppl 1):S18-22. PubMed ID: 16533625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
    Reginster JY; Felsenberg D; Cooper C; Stakkestad JA; Miller PD; Kendler DL; Adami S; McClung MR; Bolognese MA; Civitelli R; Dumont E; Bonvoisin B; Recker RR; Delmas PD
    Osteoporos Int; 2006 Feb; 17(2):159-66. PubMed ID: 15959614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
    Freemantle N; Satram-Hoang S; Tang ET; Kaur P; Macarios D; Siddhanti S; Borenstein J; Kendler DL;
    Osteoporos Int; 2012 Jan; 23(1):317-26. PubMed ID: 21927922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.